Bioptigen Awarded Phase II SBIR Grant from National Institutes of Health
Company will apply grant to research in pediatric ophthalmology.
Research Triangle Park, NC, October 05, 2011 --(PR.com)-- Bioptigen Inc., a medical-device company that has developed innovative ophthalmic imaging technologies for translational research, has been awarded a $2.7 million, 27-month grant from the National Eye Institute of the U.S. National Institutes of Health.
The company will apply the grant to the research of spectral domain optical coherence tomography (SDOCT) systems targeted to the needs of the pediatric population.
“Children have unique eye care needs,” said Dr. Eric L. Buckland, President and CEO of Bioptigen. “It is both exciting and satisfying to work on imaging tailored to the developing eye. Our objective is to provide researchers and clinicians with the comprehensive, mobile imaging they require to properly view and manage pediatric eye disease.”
The National Eye Institute grant was awarded for the investigation of technologies related to portable SDOCT imaging that could be applied to the research, diagnosis and treatment of childhood eye diseases. The goal of this research would be to enable structural and functional imaging of premature and neonatal infants using a compact, hand-held device.
Bioptigen’s high-performance optical imaging technologies support researchers and clinicians in the study of eye pathologies – equipping them to explore new avenues of understanding to advance disease detection and treatment.
The Bioptigen Envisu™ spectral domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. Envisu rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.
Bioptigen systems are deployed in nine of the top 10 ophthalmic research institutions in the country.
Bioptigen’s innovations are covered by more than 60 patent applications, including 30 awarded patents. Researchers and clinicians have published more than 100 scientific articles supported by data acquired in the use of the company’s technologies.
###
The company will apply the grant to the research of spectral domain optical coherence tomography (SDOCT) systems targeted to the needs of the pediatric population.
“Children have unique eye care needs,” said Dr. Eric L. Buckland, President and CEO of Bioptigen. “It is both exciting and satisfying to work on imaging tailored to the developing eye. Our objective is to provide researchers and clinicians with the comprehensive, mobile imaging they require to properly view and manage pediatric eye disease.”
The National Eye Institute grant was awarded for the investigation of technologies related to portable SDOCT imaging that could be applied to the research, diagnosis and treatment of childhood eye diseases. The goal of this research would be to enable structural and functional imaging of premature and neonatal infants using a compact, hand-held device.
Bioptigen’s high-performance optical imaging technologies support researchers and clinicians in the study of eye pathologies – equipping them to explore new avenues of understanding to advance disease detection and treatment.
The Bioptigen Envisu™ spectral domain ophthalmic imaging platform employs low-power incoherent light to generate high-resolution, depth-resolved images of ocular tissues. Envisu rapidly acquires and displays volumetric images suitable for real-time exploration of tissue physiology and pathology.
Bioptigen systems are deployed in nine of the top 10 ophthalmic research institutions in the country.
Bioptigen’s innovations are covered by more than 60 patent applications, including 30 awarded patents. Researchers and clinicians have published more than 100 scientific articles supported by data acquired in the use of the company’s technologies.
###
Contact
Bioptigen Inc.
Karen Stinneford
919-833-9102
www.bioptigen.com/
Karen Stinneford
919-833-9102
www.bioptigen.com/
Contact
Categories